重症急性胰腺炎患者万古霉素药代动力学及影响因素:7年数据分析
该回顾性分析纳入上海交通大学医学院附属瑞金医院ICU 2010年1月至2016年12月收治的58例重症急性胰腺炎合并G+感染患者,共134次万古霉素稳态谷浓度监测。按万古霉素使用时间分为早期组(发病21天内)、中期组(21-28天)和晚期组(超过28天)。结果显示重症急性胰腺炎患者万古霉素谷浓度显著低于15 mg/L标准[(7.5±4.3) mg/L,P<0.01],早期组和中期组谷浓度均显著低于晚期组,清除率显著高于晚期组。多因素分析显示谷浓度与血清肌酐、肌酐清除率、平均日剂量及万古霉素起始时间相关。作者认为需更高剂量方案以保证临床疗效并减少细菌耐药。
要点
- 重症急性胰腺炎患者万古霉素稳态谷浓度平均仅(7.5±4.3) mg/L,显著低于15 mg/L标准(P<0.01)。
- 用药越早谷浓度越低:早期组(5.0±2.1) mg/L、中期组(7.3±2.5) mg/L均显著低于晚期组(11.5±5.1) mg/L(均P<0.01)。
- 早期组清除率(10.5±3.0) L/h、中期组(8.1±1.9) L/h均显著高于晚期组(7.4±1.9) L/h(均P<0.05);早期组表观分布容积(73.7±15.5) L显著高于晚期组(71.0±12.6) L(P<0.05)。
- 谷浓度与血清肌酐(r=0.449)、肌酐清除率(r=-0.318)、平均日剂量(r=0.373)及万古霉素起始时间(r=0.763)相关(均P<0.05)。
- 作者认为需更高剂量方案以保证临床疗效并减少细菌耐药。
适用人群与场景
- 18-80岁重症急性胰腺炎合并G+感染、收住ICU并接受万古霉素治疗的患者。
研究设计与关键结果
- 回顾性分析纳入58例患者共134次万古霉素稳态谷浓度,早期组41例61次、中期组24例33次、晚期组28例40次。
- 三组性别、年龄、体重、血清肌酐、肌酐清除率、白蛋白、APACHE II评分无显著差异。
- 早期组、中期组与晚期组万古霉素起始时间分别为(15.9±3.2)天、(23.3±2.2)天 vs (35.0±6.7)天(均P<0.05)。
- 早期组液体正平衡低于晚期组[(1 565.2±3 132.1) mL vs (3 675.1±3 411.5) mL,P<0.01],中期组液体正平衡高于晚期组[(5 078.7±3 892.4) mL vs (3 675.1±3 411.5) mL,P<0.05]。
- 早期组、中期组、晚期组万古霉素平均日剂量分别为(14.7±5.0)、(15.0±2.8)、(17.0±4.2) mg/kg,差异无显著差异(P>0.05)。
- 重症急性胰腺炎患者万古霉素谷浓度[(7.5±4.3) mg/L]显著低于15 mg/L标准(P<0.01);表观分布容积(72.4±15.4) L,清除率(9.0±2.8) L/h。
- 早期组和中期组谷浓度[(5.0±2.1)、(7.3±2.5) mg/L]均显著低于晚期组[(11.5±5.1) mg/L](均P<0.01),清除率[10.5±3.0、8.1±1.9 L/h]均显著高于晚期组[7.4±1.9 L/h](均P<0.05);早期组表观分布容积[(73.7±15.5) L]显著高于晚期组[(71.0±12.6) L](P<0.05)。
- 多因素线性回归显示谷浓度与血清肌酐(r=0.449)、肌酐清除率(r=-0.318)、平均日剂量(r=0.373)及万古霉素起始时间(r=0.763)相关(均P<0.05)。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在重症急性胰腺炎合并G+感染患者中,万古霉素常规给药后谷浓度常低于15 mg/L目标,用药越早谷浓度越低,提示需关注早期患者的浓度监测。
- 作者认为需更高剂量方案以保证临床疗效并减少细菌耐药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the change of the serum trough concentration and its pharmacokinetics of vancomycin in patients with severe acute pancreatitis (SAP), and to analyze the factors influencing vancomycin concentration.
METHODS: A retrospective analysis was conducted. Steady-state trough concentrations of vancomycin from patients (18-80 years old) with SAP concomitantly with G+ infection admitted to Intensive Care Unit (ICU) of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine from January 2010 to December 2016 were enrolled. According to the usage time of vancomycin, the patients with SAP were divided into early group (onset within 21 days), middle group (onset between 21-28 days) and late group (onset over 28 days). The gender, age, body weight, clinical diagnosis, acute physiology and chronic health evaluation II (APACHE II) score, renal function, and the pharmacokinetic parameters were recorded. Influencing factors of vancomycin was analyzed by multiple linear regression and stepwise regression.
RESULTS: Fifty-eight patients were enrolled who contained 134 times trough concentrations of vancomycin. There were 41 patients enrolled and 61 times of trough concentrations in the early group, 24 patients enrolled and 33 times of trough concentrations in the middle group, and 28 patients enrolled and 40 times of trough concentrations in the late group. There was no significant difference in gender, age, body weight, serum creatinine, creatinine clearance (CCr), albumin, APACHE II score among the three groups. There was significantly difference in the duration from the onset time to vancomycin administration between early, middle groups and late group (days: 15.9±3.2, 23.3±2.2 vs. 35.0±6.7, both P < 0.05). The positive liquid balance in early group was lower than that of late group (mL: 1 565.2±3 132.1 vs. 3 675.1±3 411.5, P < 0.01), while it was increased in the middle group as compared with that of late group (mL: 5 078.7±3 892.4 vs. 3 675.1±3 411.5, P < 0.05). The average daily dose of vancomycin in the early, middle and late groups were (14.7±5.0), (15.0±2.8), (17.0±4.2) mg/kg, respectively, and there was no significant difference (P > 0.05). Compared with the standard concentration (15 mg/L) of vancomycin, the serum trough concentration of vancomycin was significantly reduced in SAP patients [(7.5±4.3) mg/L, P < 0.01]. Apparent volume of distribution (Vd) was (72.4±15.4) L, and clearance rate (CL) was (9.0±2.8) L/h. According to the Bayesian, the serum trough concentration of vancomycin was significantly reduced in early group and middle group compared with late group (mg/L: 5.0±2.1, 7.3±2.5 vs. 11.5±5.1, both P < 0.01), CL was significantly increased (L/h: 10.5±3.0, 8.1±1.9 vs. 7.4±1.9, both P < 0.05), and Vd was significantly increased in early group compared with late group (L: 73.7±15.5 vs. 71.0±12.6, P < 0.05). It was shown by multiple linear regression analysis that there was strong relationship between serum trough concentration and the serum creatinine, CCr, average daily dose and the starting time of vancomycin treatment (r value were 0.449, -0.318, 0.373, 0.763, respectively, all P < 0.05).
CONCLUSIONS: The serum trough concentration of vancomycin was significantly reduced in SAP patients. And the earlier usage of vancomycin, the lower of the trough concentration is. Therefore, higher dosage regimen was needed to ensure the clinical effect, and reduce the bacterial resistance.
参考来源
- He J, Mao E, Jing F, et al. [Pharmacokinetics of vancomycin in patients with severe acute pancreatitis and its influencing factors: analysis of 7 years data]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625235. doi:10.3760/cma.j.issn.2095-4352.2017.06.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。